<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3875">
  <stage>Registered</stage>
  <submitdate>18/02/2013</submitdate>
  <approvaldate>18/02/2013</approvaldate>
  <nctid>NCT01802814</nctid>
  <trial_identification>
    <studytitle>International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010</studytitle>
    <scientifictitle>International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IntReALL SR 2010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Lymphoblastic Leukemia (ALL)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SR-A + Epratuzumab
Treatment: drugs - SR-B + Epratuzumab

No Intervention: SR-A - Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.

Active Comparator: SR-A + Epratuzumab - Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab.

No Intervention: SR-B - Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab.

Active Comparator: SR-B + Epratuzumab - Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab.


Treatment: drugs: SR-A + Epratuzumab


Treatment: drugs: SR-B + Epratuzumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>SR induction/consolidation ALL-REZ BFM 2002 versus UK-ALL-R3 (randomisation 1) - SR induction/consolidation ALL-REZ BFM 2002 versus UK-ALL-R3 (randomisation 1): 10% pEFS superiority of arm B above a 65% pEFS at 4 years of arm A</outcome>
      <timepoint>at 4 years of arm A</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>SR consolidation +/- epratuzumab (randomisation 2) - SR consolidation +/- epratuzumab (randomisation 2): 10% pEFS superiority of the arm with epratuzumab above an expected 74% pEFS at 4 years of the standard arm</outcome>
      <timepoint>at 4 years of standard arm</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>SR induction/consolidation - SR induction/consolidation: comparison of OS, toxicity, rate of CR2, and rate of MRD between treatment groups</outcome>
      <timepoint>year 7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SR consolidation +/- epratuzumab - SR consolidation +/- epratuzumab: comparison of OS, toxicity, MRD levels, rate of MRD and evaluation of pharmacokinetic parameters of Epratuzumab</outcome>
      <timepoint>year 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Morphologically confirmed diagnosis of 1st relapsed precursor B-cell or T-cell ALL

          -  Children less than 18 years of age at inclusion

          -  Meeting SR criteria: late isolated or late/early combined BCP BM relapse, any
             late/early isolated extramedullary relapse

          -  Patient enrolled in a participating centre

          -  Written informed consent

          -  Start of treatment falling into the study period

          -  No participation in other clinical trials 30 days prior to study enrolment that
             interfere with this protocol, except trials for primary ALL Inclusion criteria
             specific for the epratuzumab randomization

          -  Precursor B-cell immunophenotype. A specific CD22 expression level is not required

          -  M1 or M2 status of the bone marrow after induction</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>17</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  BCR-ABL / t(9;22) positive ALL

          -  Pregnancy or positive pregnancy test (urine sample positive for ß-HCG &gt; 10 U/l)

          -  Sexually active adolescents not willing to use highly effective contraceptive method
             (pearl index &lt;1) until 2 years after end of antileukemic therapy

          -  Breast feeding

          -  Relapse post allogeneic stem-cell transplantation

          -  The whole protocol or essential parts are declined either by patient himself/herself
             or the respective legal guardian

          -  No consent is given for saving and propagation of pseudonymized medical data for study
             reasons

          -  Severe concomitant disease that does not allow treatment according to the protocol at
             the investigator's discretion (e.g. malformation syndromes, cardiac malformations,
             metabolic disorders)

          -  Karnovsky / Lansky score &lt; 50%

          -  Subjects unwilling or unable to comply with the study procedures

          -  Subjects who are legally detained in an official institute</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1242</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Australian &amp; New Zealand Childhood Hematology &amp; Oncology Group - Clayton</hospital>
    <postcode>3168 - Clayton</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University Hospital of Berlin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main goal of this study is to improve the outcome of children and adolescents with
      standard risk first relapsed acute lymphoblastic leukemia. Furthermore, goal is to set up a
      large international study group platform allowing for optimization of standard treatment
      strategies and integration of new agents.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01802814</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Arend von Stackelberg, MD</name>
      <address>University Hospital of Berlin - Charité</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Arend von Stackelberg, MD</name>
      <address />
      <phone>+49(0)30-450666</phone>
      <fax />
      <email>arend.stackelberg@charite.de</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>